Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab

Br J Dermatol. 2021 Oct;185(4):865-867. doi: 10.1111/bjd.20527. Epub 2021 Aug 10.

Authors

P M Brunner¹, C Conrad², R Vender³, S Grond⁴, C Schuster^{1

4}, H Patel⁴, W Xu⁴, J M Carrascosa Carrillo⁵

Affiliations

¹ Department of Dermatology, Medical University of Vienna, Vienna, Austria.
² Department of Dermatology, Lausanne University Hospital CHUV, Lausanne, Switzerland.
³ Dermatrials Research Inc, Hamilton, ON, Canada.
⁴ Eli Lilly and Company, Indianapolis, IN, USA.
⁵ Department of Dermatology, Hospital Universitari Germans Trias I Pujol, Universitat Autònoma de Barcelona, Barcelona, Spain.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Dermatologic Agents* / adverse effects
Etanercept / adverse effects
Humans
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome
Ustekinumab / adverse effects

Substances

Antibodies, Monoclonal, Humanized
Dermatologic Agents
ixekizumab
Ustekinumab
Etanercept